Excellent performance by new drugs at AstraZeneca led to 18% growth in the group’s sales, while the core operating profit grew by 8%, both outperforming the street as well as our expectations. Oncology continued to be at the forefront of this growth, supported by CVRM and respiratory. Top-line guidance for the year was upped, while core EPS guidance was maintained.
26 Jul 2019
The 2Cs - Cancer and China – underpin the guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The 2Cs - Cancer and China – underpin the guidance upgrade
AstraZeneca PLC (AZN:LON) | 11,224 2020.3 0.2% | Mkt Cap: 173,998m
- Published:
26 Jul 2019 -
Author:
Kamla Singh -
Pages:
3
Excellent performance by new drugs at AstraZeneca led to 18% growth in the group’s sales, while the core operating profit grew by 8%, both outperforming the street as well as our expectations. Oncology continued to be at the forefront of this growth, supported by CVRM and respiratory. Top-line guidance for the year was upped, while core EPS guidance was maintained.